pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
996
stories
27d
Roche puts numbers behind phase 3 kidney disease win amid blockbuster ambitions
fiercebiotech
27d
ESMO: Takeda’s $1.2B bet on Innovent ‘absolutely’ pays off with details of ADC’s phase 3 win
fiercebiotech
27d
Roche pays Zymeworks $55M for trispecific challenger to Amgen’s Imdelltra
fiercebiotech
28d
Protein degrader specialist Lycia prices $318M IPO
biopharma dive
28d
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
biospace
28d
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
biopharma dive
28d
STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
stat
28d
Biotech notches 31 IPOs already this year, with 4 more joining queue
biospace
28d
GSK, Ionis hepatitis B functional cure breaks open market for followers
biospace
28d
STAT+: What to expect from the Moderna-Merck cancer vaccine data reveal
stat
28d
STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
stat
28d
Roivant's TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease
biospace
28d
Celltrion picks up another Kaigene autoimmune antibody for up to $580.5M
fiercebiotech
28d
Menarini's Stemline picks up Georgiamune preclinical cancer immunotherapy in $1.1B deal
fiercebiotech
28d
Critical decisions that spurred these 40 Under 40 winners to success
biospace
29d
ESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up
fiercebiotech
29d
STAT+: Another diabetes association leader is out while review continues
stat
29d
GSK, Ionis win US approval for first-of-its-kind hepatitis B drug
biopharma dive
29d
Roivant, continuing ascent, claims another victory for rare disease drug
biopharma dive
29d
Roivant's autoimmune drug succeeds in two pivotal trials, setting up 2027 filing
endpoints
29d
STAT+: GSK picks up hep B drug approval
stat
29d
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
biospace
29d
GSK, Ionis win FDA nod for hepatitis B functional cure that controls virus after treatment
biospace
29d
STAT+: Roivant says closely watched immune drug succeeded in new eye disease
stat
29d
A counterintuitive way to build trust in measles vaccines and public health
stat
29d
The 6 biggest crossover rounds in biopharma history
biospace
Oct 20, 26
‘A two-way conversation with the tumor’: Researchers use ‘avatar’ to predict immunotherapy responses
fiercebiotech
Oct 20, 26
Pfizer ends Phase 2 autoimmune study; Lycia aims for $227M IPO
endpoints
Oct 20, 26
How voters feel about trans rights and abortion access will soon be put to the test
stat
Oct 20, 26
Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform
biospace
← prev
page 7 of 34
next →